@article{ref1,
title="Euthanasia and/or medically assisted suicide: Reflection on the new responsibility of the hospital pharmacist",
journal="Annales Pharmaceutiques Francaises",
year="2014",
author="Boissinot, L. and Benamou, M. and Léglise, P. and Mancret, R.-c. and Huchon-Bécel, D.",
volume="72",
number="2",
pages="82-89",
abstract="Context: Concern about euthanasia and medically assisted suicide is currently growing around the world and particularly in France. Though not authorized at present in France, the role of hospital pharmacist in this issue needs to be discussed. <br><br>OBJECTIVES: This article aims to gather medical and legal literature of European Union member states on these issues and particularly in France. To propose a practical thinking on the possible role of hospital pharmacist. <br><br>RESULTS: Among European Union, euthanasia and/or assisted suicide have already been introduced in some member states' laws. In France, Leonetti law currently sets the legal framework for the management of end of life. To address the society's demand on these issues, French President F. Hollande made two ethics committees responsible for working on it. Both were mainly against euthanasia and assisted suicide. Though a bit forgotten in this debate, hospital pharmacist needs to be associated in the thinking, as the main &quot;drug-keeper&quot;. Indeed, guidelines are necessary to outline and ensure a safe drug use, complying with professional ethics, if lethal doses are voluntarily prescribed. <br><br>CONCLUSION: Pharmaceutical work is in constant evolution and is addressing new issues still unanswered, including assisted suicide and euthanasia. French pharmaceutical authorities should seize upon them, in order to guarantee pharmaceutical ethics. These practices, if authorized by law, should remain exceptional, and law strictly enforced. The pharmacist could be one of these &quot;lawkeepers&quot;. © 2014 Elsevier Masson SAS.<p /><p>Language: fr</p>",
language="fr",
issn="0003-4509",
doi="10.1016/j.pharma.2013.12.004",
url="http://dx.doi.org/10.1016/j.pharma.2013.12.004"
}